Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenScript Completes Phase I of Nanjing Biologics CDMO R&D/Production Center

publication date: Jul 19, 2019

GenScript Biotech, a biologics CDMO, has completed construction of its R&D and production center in Nanjing. When fully operational, the center will offer a full end-to-end suite of biological services, starting with pre-clinical research, and continuing into commercial production. The company's biologics GMP production center, which is expected to start production in 2020, will have 2,600 liters of capacity, enough for Phase I and II clinical supply. GenScript has a well-established global business that supplies custom synthesized genes for research. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital